Clinical Study Data Request Registered Users, Please Login

Scroll down the list of studies provided below. Studies are listed by study medicine in alphabetical order. Alternatively you can browse the list of studies using the search function.

To select studies and submit a research proposal or enquiry, go back to the Home page and select View and submit.

This takes you back to the previous page to enable you to view studies from a different sponsor.

Select medicine, medical condition or phase from the drop down boxes. This searches all the available clinical studies. Selecting from more than one drop down box will “and” the criteria.

Find by:


Alternatively search for studies using the Roche Clinical Study Identification Number or study title by entering text and clicking search.

 

187 found

Click the study title to find more information about the study.

ROCHE-AVF4200G/BO20904
(AVAGAST) A Double-blind, Randomised, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-line Therapy in Patients With Advanced Gastric Cancer

Medicine: bevacizumab, Condition: gastric cancer, Phase: 3, Clinical Study ID: AVF4200G/BO20904, Sponsor: Roche.
ROCHE-ML22367
(AVATAR) A Double-Blind, Randomized, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-Line Therapy in Patients With Advanced Gastric Cancer.

Medicine: bevacizumab, Condition: gastric cancer, Phase: 3, Clinical Study ID: ML22367, Sponsor: Roche.
*ROCHE-A0276G
Thrombolytic Therapy in Acute Ischemic Stroke (Atlantis: Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke)

Medicine: Activase, Condition: acute ischemic stroke, Phase: 2/3, Clinical Study ID: A0276G, Sponsor: Roche
*ROCHE-A2055G
A Randomized, Double-Blind, Placebo-controlled Study of Recombinant Tissue Plasminogen Activator (rt-PA) for the Restoration of Function to Central Venous Access Devices

Medicine: Activase, Condition: Central Venous Access Devices, Phase: 3, Clinical Study ID: A2055G, Sponsor: Roche
*ROCHE-A2065G
An Open-Label Study of the Safety of Alteplase in the Treatment of Subjects with Dysfunctional Central Venous Access Devices

Medicine: Activase, Condition: Central Venous Access Devices, Phase: 3, Clinical Study ID: A2065G, Sponsor: Roche
ROCHE-APM4074g
A randomized, double-blind, phase ii trial of paclitaxel plus carboplatin plus bevacizumab with or without apomab in patients with previously untreated, advanced-stage non-small cell lung cancer

Medicine: apomab (Anti-DR5; PRO95780), Condition: advanced-stage non-small cell lung cancer, Phase: 2, Clinical Study ID: APM4074g, Sponsor: Roche
ROCHE-AVF2119G
A multicenter, open-label, phase III, randomized, active-controlled trial evaluating the efficacy, safety, and pharmacokinetics of rhuMAb VEGF (bevacizumab), in combination with capecitabine chemotherapy, in subjects with previously treated metastatic breast cancer

Medicine: bevacizumab, Condition: refractory metastatic breast cancer, Phase: 3, Clinical Study ID: AVF2119G, Sponsor: Roche
ROCHE-BO17708
A randomized, double-blind study of the effect of first line treatment with Avastin (bevacizumab) in combination with docetaxel on progression-free survival and disease response in patients with HER2 negative metastatic breast cancer

Medicine: bevacizumab, Condition: malignant neoplasm of breast, Phase: 3, Clinical Study ID: BO17708, Sponsor: Roche
ROCHE-AVF3694G
A multicenter, phase III, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously untreated metastatic breast cancer

Medicine: bevacizumab, Condition: malignant neoplasm breast unspecified site, Phase: 3, Clinical Study ID: AVF3694G, Sponsor: Roche
ROCHE-ML18147
A randomized, open-label phase III Intergroup study: Effect of adding Bevacizumab to cross over fluoropyrimidine based chemotherapy in patients with mCRC and disease progression under first-line standard CTx/Bevacizumab combination

Medicine: bevacizumab, Condition: malignant neoplasm of colon/rectum, Phase: 3, Clinical Study ID: ML18147, Sponsor: Roche
First Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Next Last